More on IVBIY

- Summary
- Chart
- Profile
- Historical

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

(OP:IVBIY)
Delayed: 54.29 --0 (-0%)
Prev. Close $54.29  
Open$54.29 
52 Wk High$ 
52 Wk Low$ 
Day High$54.29 
Day Low$54.29 
P/E N/A  
EPS$ 
Volume14 

Friends, Peers and Foes (?): 6IB, 83B, 3NX LLY (more...)

Sep 23, 2026 04:48 AM Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting
Aug 25, 2026 06:15 AM Innovent Announces 2026 Interim Results and Business Updates
Aug 9, 2026 08:00 PM Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China
Aug 5, 2026 08:00 PM Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal
Jul 14, 2026 06:00 AM Spero Therapeutics licenses Innovent antibody in deal worth up to $1.1B
Jul 14, 2026 06:00 AM Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
Jun 30, 2026 12:00 AM Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
Jun 24, 2026 08:00 PM Ollin Biosciences raises $330M Series B to fund eye disease trials
Jun 24, 2026 08:00 PM Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second
Jun 21, 2026 08:00 PM Innovent begins Phase 3 trial of tri-specific antibody for myeloma
View All Articles

Entities mentioned with IVBIY

View All Entities